Long‐term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli‐durability 24‐month observational study
Authors' conclusion
iGlarLixi initiation was associated with improved glycaemic control, without body weight change or increased hypoglycaemia over 24 months.
Study context
- Population
- Adults ≥18 years with T2D previously treated with oral antidiabetic drugs ± basal insulin or GLP-1 RA, initiating iGlarLixi 1 January 2017–31 March 2020, US; mean age 58.4 years, 52.6% female
- Participants
- 1,685 adults
- Outcome
- Change in HbA1c
- Follow-up
- 24 months after starting iGlarLixi
Methodological detailssingle-group, claims database (Optum Market Clarity®)
- Single-group
- Claims database (Optum Market Clarity®)
Main finding
As reported in the abstract
Change in HbA1c (overall population, including imputed values) · 24 months
Mean ± SD HbA1c at baseline
9.3 ± 1.8%
Mean ± SD HbA1c at 24 months
8.3 ± 1.8%
Reduction in HbA1c from baseline
0.9%
Observational data: associations, not effects.
Secondary outcomes
HbA1c target <7% achieved · 24 months
- Achieved HbA1c <7%
- 22.2%
Body weight · baseline to 24 months
- Mean ± SD body weight at baseline
- 102.1 ± 24.2 kg
- Mean ± SD body weight at 24 months
- 101.9 ± 23.3 kg
- Body weight remained stable
Safety
Hypoglycaemia event rate · baseline to 24 months
- Baseline
- 16.1 P100PY
- 24 months (decreased)
- 11.4 P100PY
Original publication
Long‐term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli‐durability 24‐month observational study. Diabetes Obes Metab. Published 11 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →